PharmaEngine
4162.TWO
1.83 USD
-0.01
-0.54%
p
Overview
Last close
1.83 usd
Market cap
259.73M usd
52 week high
3.68 usd
52 week low
1.77 usd
Target price
3.76 usd
Valuation
P/E
21.7472
Forward P/E
N/A
Price/Sales
9.0937
Price/Book Value
1.6969
Enterprise Value
115.46M usd
EV/Revenue
4.0423
EV/EBITDA
7.0921
Key financials
Revenue TTM
28.56M usd
Gross Profit TTM
26.94M usd
EBITDA TTM
13.65M usd
Earnings per Share
0.08 usd
Dividend
N/A usd
Total assets
163.99M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
